Menu Contact Us Home Capabilities Our Team In The Media LifeSci Partners Copyright 2021 LifeSci Communications Blog

Clients in the Media LifeSci Communications Clients in the Media

Clene Inc. (CLNN) CEO Rob Etherington On Neurodegenerative Disease

Nicole hosts Rob Etherington, the CEO of the clinical-stage biopharmaceutical company Clene (CLNN), to discuss the company’s latest progress on its treatments for Parkinson’s and…

View clip

Putting Pressure On Cells to Kill Cancer

Sotio’s cell platform, called DCVAC, starts with a patient’s peripheral blood mononuclear cells, which are grown into dendritic cells (DCs). In parallel, the company uses…

READ MORE

‘Never been more urgent:’ Scynexis looks to tackle superbug crisis with late-stage readout for antifungal hopeful

As the superbug crisis heats up around the world, Scynexis says it has new data from two interim analyses that prove its antifungal has the…

READ MORE

Pivots During Pandemic Bring Patient-Centric Options to Rare Disease Patients

X4 Pharmaceuticals is developing a class of small molecule therapeutics that work as antagonists of chemokine receptor, CXCR4, the disruption of which is implicated in a…

READ MORE

Looking to take advantage of ‘silenced’ enzymes, SalioGen emerges from stealth with eyes set on gene therapy 3.0

That’s the question a new biotech is aiming to answer, as SalioGen Therapeutics emerges from stealth Monday morning with a $20 million Series A. And…

READ MORE

The Fight Against Fungi

Cidara Therapeutics is exploring echinocandin derivatives. The company’s clinical candidate rezafungin is a derivative of anidulafungin, a compound originally discovered at Eli Lilly and Company and…

READ MORE

Developing Oral Drugs for Neurodegenerative Diseases Based on Bioenergetic Nanotherapeutics with Mark Mortenson Clene Nanomedicine

Mark Mortenson, Chief Science Officer, Clene Nanomedicine is combining physics with biology to develop its bioenergetic nanocatalyst drug candidates that accelerate neurorepair for patients with…

Listen here

A three way battle beckons in GM1 gangliosidosis

Sio Gene Therapies’ AXO-AAV-GM1 and Passage Bio’s PBGM01 – are due to yield data in mid-2021, and Lysogene is not too far behind with LYS-GM101. Within…

READ MORE

A diagnostics company completes its pharma makeover, rebranding as Fore with Immunomedics vet at the helm

As part of the change in direction, Fore has appointed Usama Malik as CEO, a former key player at Immunomedics during their $21 billion acquisition…

READ MORE

Novellus becomes Fore Biotherapeutics as it completes pivot from diagnostics to precision oncology

NovellusDx started out as a diagnostics company but has been making moves toward becoming a cancer therapeutics biotech in recent months, picking up a BRAF…

READ MORE

As mutant COVID variants multiply, the hunt is on for a ‘universal’ kill-all vaccine

French company Valneva, meanwhile, is working on an inactivated vaccine using the whole virus that might have advantages over those already approved, Thomas Lingelbach, the…

READ MORE

Pfizer chips in on $26M raise for rheumatoid arthritis collaborator; Hansoh licenses an anti-fungal for a mysterious infection

Chinese pharma powerhouse Hansoh has a new partner, teaming with the New Jersey biotech Scynexis to develop a drug that has recently gained attention for…

READ MORE

Advancing neutralising antibody therapies for COVID-19

In this article, Ian Chan, Chief Executive Officer and Co-Founder of biotech company Abpro, discusses the development of neutralising antibodies for SARS-CoV-2. Abpro’s neutralising antibody…

READ MORE

Targeting a Key Marker of Clotting and Inflammation in COVID-19 Patients

CalciMedica has developed Auxora, a calcium release-activated calcium (CRAC) channel inhibitor, and it has shown it can reduce the levels of D-dimer, a key biomarker…

READ MORE

Anima Biotech’s mRNA Technology is Lighting Up Novel Drug Targets

Thanks to the Pfizer/BioNTech and Moderna COVID-19 vaccines, it is likely you have heard the term mRNA. However, it is unlikely you have heard it…

READ MORE

John Temperato: CEO of 9 Meters Biopharm‪a‬

John Temperato, President and Chief Executive Officer of 9 Meters Biopharma, speaks with BioBoss host John Simboli about leadership in biopharma and how 9 Meters…

Listen here

Heat Biologics shares sizzle as new phase II NSCLC data put it on path to possible pivotal trial

New interim phase II data in advanced non-small-cell lung cancer (NSCLC) has shown that a combination of Heat Biologics Inc.’s cell therapy candidate, HS-110 (viagenpumatucel-L),…

READ MORE

Valneva Eyes Head-to-Head Vaccine Trial

Thomas Lingelbach, chief executive officer at Valneva SE, discusses the company’s vaccine trials, the difference in processes in working with the U.K. versus the EU…

View clip

Raleigh company working to develop a cure for celiac disease

“One of the beauties of being in biotech is that at the end of what you do you improve the lives of debilitating diseases,” said…

READ MORE

Disease Cancelling Technology Emulates Sound Cancelling Technology to Mute Cancer

Immuneering prefers the hum of purposeful activity to mere noise. That helps explain why the company develops drugs to dampen the cacophony of cell signalling…

READ MORE

CalciMedica’s Auxora reduces D-Dimer levels in Covid-19 trial

CalciMedica has reported positive clinical data from the trial of its lead clinical compound, Auxora, in patients with severe Covid-19 pneumonia.

READ MORE

Quellor clinical study underway to lessen COVID-19 symptoms

That drug is called Quellor. INmune BIO said if its drug is approved by the FDA, the hope is it could reduce symptoms of COVID-19…

READ MORE

Ibrexafungerp advances the fight against fungus

In December, SCYNEXIS Inc. reported progress on ibrexafungerp’s intravenous (IV) formulation and provided an update on the therapy’s ongoing Phase 3 studies in the hospital…

READ MORE

Clene Nanomedicine Secures Crucial Patent for Gold Nanocrystal MS Treatment

Clene Nanomedicine was awarded a crucial patent from the U.S. Patent and Trademark Office for its patented clean-surfaced gold nanocrystals used for treating patients with multiple sclerosis.

READ MORE

Exploring the Therapeutic Value of Blood Components

Convalescent plasma (CP) is plasma obtained from patients who have recovered from an infectious illness and thus generated antibodies to the disease. It can be…

READ MORE

New COVID-19 variant has emerged in California, says Dr. Patrick Soon-Shiong

A new variant of COVID-19 has been detected in California, and it is entirely different from other variants found recently in the U.K. and South…

View clip

Valneva begins manufacturing vaccine candidate in Scotland

French biotech Valneva has started manufacturing its vaccine candidate in Scotland, the U.K. government announced Thursday. The move follows a multi-million-pound joint investment in the…

READ MORE

J.P. Morgan: Will Biotech’s Virtual 2021 Launch Become the New Reality?

“J.P. Morgan and the meetings around J.P. Morgan are such a fun week for us in the industry typically, but I have to be blunt:…

READ MORE

Nirogy Therapeutics emerges with $16.5M to target metabolite transporters

After years working under the radar, Nirogy Therapeutics is officially launching with $16.5 million and a mission to drug a family of membrane proteins called…

READ MORE

XPro1595 significantly improves neurodegeneration in AD trial

INmune Bio, Inc., who developed the drug, noted that the analysis highlighted an approximate two-fold reduction in the neurodegeneration markers visinin-like protein 1 (VILIP-1) and…

READ MORE

Tackling Covid-19 variants with next-generation vaccines

When SARS-CoV-2 emerged on to the global stage in early 2020, many pharma groups leapt into action. After receiving the genetic code of the emerging…

READ MORE

In the pipeline: What the next wave of COVID-19 vaccines could look like

We take a look at some of the COVID-19 vaccine candidates moving through Phase 1 and 2 clinical trials – and how they could offer…

READ MORE

Acepodia’s Approach To ACC & CAR Manufacturing Scalability

Acepodia CEO, President, & Co-founder Dr. Sony Hsiao and Dr. Mark Gilbert, VP of R&D, join Erin Harris and Matt Pillar for a discussion on…

Listen here

Rogue antibodies could be driving severe COVID-19

Finding a rock-solid connection can be tough, because it’s difficult to show whether the infections are the cause of autoimmune disorders or whether they crop…

READ MORE

Clene Nanomedicine Aims to be the ‘Gold Standard’ in Neurodegenerative Disease

Clene Nanomedicine, one of Maryland’s Future 2020 companies, closed a merger with Tottenham Acquisition I Limited that provided the company with a slot on the…

READ MORE

Disease-cancelling drugs: Immuneering raises $62m in Series B round

Immuneering has raised $62m in an oversubscribed Series B round led by high-profile life science investors. The money will be used to support the company’s…

READ MORE

JPM: Aridis CEO Truong on why the pandemic hasn’t bolstered antibiotics R&D and what needs to change

With its pipeline of bacteria-fighting monoclonal antibodies, Aridis is working to tackle the first two problems: injecting innovation into the space and testing its programs…

READ MORE

Here’s What 4 Biopharma CFOs Think About The Future Of Remote Work

Office interactions are definitely an important way to foster relationships between coworkers, establish and maintain a corporate culture, and foster creative thinking. This is particularly…

READ MORE

Biopharma Executive Perspectives on 2021

“The biggest thing that is really happening in the biotech industry…there is a new rich source of drugs. There is a goldmine, called mRNA, that…

READ MORE

Health-Care Venture Capitalists Raised Record Total in 2020

Immuneering Corp., a Cambridge, Mass.-based startup that uses computational technology for drug discovery, completed a $62 million Series B round. Cormorant Asset Management led the…

READ MORE

Using Computational Discovery to Build Better Immunotherapies

Compugen is using a computational discovery platform to identify proteins and pathways that drive immune resistance mechanisms to checkpoint inhibitors. We spoke to Anat Cohen-Dayag,…

Listen here

What We Know About Narcolepsy, Sodium Oxybate Use, Salt Intake & Cardiovascular Risk

The review received financial support from Avadel Pharmaceuticals, which recently filed a new drug application  with the US Food & Drug Administration (FDA) for a…

READ MORE

Immuneering secures $62M series B to advance tech-driven pipeline

Immuneering Corp., a bioinformatics specialist that has for years helped big companies like Teva Pharmaceutical Ltd. and Bristol Myers Squibb Co. better understand their own…

READ MORE

Clene goes public with gold-based neurology nanotechnology

Biotech Clene Nanomedicine has gone public with a mission to use nanotherapeutics that will use gold to treat devastating neurological diseasesincluding Parkinson’s disease.

READ MORE

Immuneering, Terns raise crossover rounds as IPO queue stands to grow again

With crossover investors lining up to participate, biotechs Immuneering and Terns each raised…

READ MORE

Using Protein Characterization to Support Regulatory Submissions

Before any biologic drug enters into the clinic, it is essential to have a clear understanding of what exactly the biomolecule entails, according to Vu…

READ MORE

New and Emerging Drug Classes That Will Outlast the Pandemic

OncoSec’s vaccine, CORVax12, being developed in partnership with Providence Cancer Center in Portland, uses a DNA-encodable stabilized trimeric SARS-CoV-2 spike glycoprotein developed in the National…

READ MORE

A year in Longevity: science perspectives

August was also Healthy Aging Month and, to get some perspective on the topic, we spoke to Stanford’s Dr Thomas Rando, best known for his…

READ MORE

Dr. Ragan Discusses X4’s Work To Advance Disease-Modifying For Rare Genetic Diseases | Podcast

Dr. Ragan discusses X4 Pharmaceuticals, which is currently developing therapies for rare genetic diseases that result from dysfunction of the immune system and is currently…

View clip

Developing Effective COVID-19 Oral Vaccine in Tablet Form with Sean Tucker Vaxart

Sean Tucker, Founder and Chief Scientific Officer, Vaxart is on a mission to expand the choices for a COVID-19 vaccine by producing an effective oral…

Listen here

Peptidream, Amolyt alliance focuses on potential acromegaly treatment

Peptidream Inc. inked a research collaboration with Amolyt Pharma SAS to test and optimize Peptidream’s growth hormone receptor antagonist (GHRA) peptides, with the aim of…

READ MORE

X4 Pharma Adjusts Clinical Trials For A COVID World

X4 Pharma is a company focused on delivering innovative treatments for patients with rare diseases of the immune system. With the COVID pandemic afflicting patients…

READ MORE

Seneca Biopharma merges with Leading BioSciences, becoming Palisade Bio

Penny stock biotech Seneca Biopharma has found a lifeline in privately owned Leading BioSciences as it merges with the biotech.

READ MORE

Dr. CJ Barnum of INmune Bio | NIH Grant tests Neuroinflammation on Treatment Resistent Depression

We sit down with Dr. CJ Barnum, Director of Neuroscience at Inmune Bio, Inc. to talk about the recently announced grant from the NIH for…

View clip

Buffalo-formed company Athenex gets FDA approval for cancer drug

Buffalo-formed biopharmaceutical company Athenex just got FDA approval for a topical ointment to treat it, called Klisyri.

READ MORE

Sio Gene Therapies posts positive PhI/II data in rare pediatric disease, the first readout since its name change

A little over a month after a full company rebrand, the Biotech Formerly Known as Axovant has its first data readout under its new moniker.

READ MORE

Bypassing Bioprocessing in Antibiotic Production

Scientists at Recce design these antibiotics to attach to proteins in the plasma membrane of pathogens via hydrophobic interactions, which trigger cell lysis. “The bacteria…

READ MORE

6 CEOs Weigh In On The Supply Chain, Nationalism, And The Reshoring Of Biopharma Manufacturing

At a macro level across the globe, there is an increasing cadence, on an exponential curve, in the ability to translate basic insights into therapeutics.…

READ MORE

The Editors’ views: Drug Target Review’s 2020 round-up

GigaGen Inc.’s co-founder and Chief Executive Officer, explained that for decades scientists working with emerging pathogens had been concerned about the possibility of a pandemic,…

READ MORE

The Race Against Mutation: How Vaccines Will Keep Up as the Coronavirus Evolves

One such company is Vaxart, based in South San Francisco, which is currently in Phase 1 human trials for a COVID-19 vaccine that’s taken as…

READ MORE

Aridis’ At-Home COVID-19 Therapy and Other Programs Primed for 2021 Inflections

Next year could be pivotal for Aridis. It anticipates inflection points for three immunotherapy programs and is making available for licensing its rapid mAb development…

READ MORE

Rocket Pharmaceuticals Surges To 5-Year High On Promising Gene Therapy

Rocket Pharmaceuticals (RCKT) announced positive Phase 1 test results for a gene therapy in heart disease — prompting RCKT stock to surge Wednesday.

READ MORE

Biotechs Developing Innovative Ways to Activate the Immune System Against COVID-19

Abpro Corp., a biotechnology company developing next generation antibody therapies for severe disease, is targeting a more robust antibody response with its therapeutic, ABP 300,…

READ MORE

Latest data give Rocket clear path forward in rare CV disease Danon

While an adverse event in the high-dose cohort continues to outline the limits oh high volume AAV dosing…

READ MORE

View From The Inside: What’s Shaping Biopharma In 2021 And Beyond?

About a year ago, Life Science Leader Chief Editor Rob Wright posed questions to several biopharma leaders for a column in the 2019 iteration of this annual…

READ MORE

2020 Top 10 Innovations

Enter GigaGen’s Surge platform, which uses single-cell sequencing to “capture and recreate” libraries of antibodies from blood donors.

READ MORE

Trial Drug Shows Promise in Treating Cognitive Impairment Associated with Schizophrenia

Last week, privately-owned Cerevance released data from a Phase Ib biomarker study of its oral compound, CVN058, evaluating the potential of the medication as a…

READ MORE

Genetic medicines find a heartbeat

“RNA interference is often better than antibodies because of the catalytic process that you can generally use,” said Chris Anzalone, CEO of Arrowhead Pharmaceuticals. A…

READ MORE

Emerging fungal resistance: A hidden epidemic

Invasive fungal infections are becoming increasingly common and often pose a serious public health threat, claiming the lives of more than 1.5 million people worldwide…

READ MORE

New Class of Drugs Harnesses Gold Nanocrystals to Heal and Protect the Brain

Clene Nanomedicine is trying to set a new “gold standard” in neurodegenerative diseases through the development of a new class of drugs called bioenergetic nanotherapeutics…

READ MORE

Targeting Calcium Overload Could Improve Stroke Outcomes

“We are fortunate to collaborate with CalciMedica, a pharmaceutical company who specializes in developing drugs suppressing calcium overload in the immune cells,” Tvrdik said. “We…

READ MORE

Scientists race to find ‘warm’ Covid vaccine to solve issue of cold storage

Vaxart, a San Francisco-based biotechnology company, is testing a tablet-form Covid-19 vaccine to tackle storage temperature problems, which affect even rich countries like the US,…

READ MORE

One Fourth of Maryland’s Future 20 are Life Science Companies

Clene Nanomedicine is a clinical-stage biopharmaceutical company focused on treating neurodegenerative diseases. Its chief asset is CNM-Au8, a bioenergetic nanocatalyst under development as an add-on…

READ MORE

Treating Cognitive Impairment in Patients with Schizophrenia

The drug in question, Cerevance, significantly improved cognitive impairments in patients suffering from schizophrenia. Dr Margolin discusses the structure of the drug trail, details the…

READ MORE

New Oncology Therapies Emerge Amidst COVID Pandemic

Cue Biopharma has managed to persevere through the COVID pandemic by employing a variety of strategies. President and Chief Scientific Officer, Anish Suri, and Ken…

READ MORE

Chiasma set for EMA filing based on acromegaly data

Chiasma was trading 4% higher in the opening minutes on Wednesday.

READ MORE